Cytosine-Based TET Enzyme Inhibitors

Area of Science:

• Epigenetics
• Molecular Biology
• Medicinal Chemistry

Background:

• DNA methylation is a key epigenetic regulator of gene transcription, vital for cellular processes.
• Dysregulation of DNA methylation is implicated in diseases like cancer.
• TET enzymes catalyze DNA demethylation, reversing methylation patterns.

Purpose of the Study:

• To design, synthesize, and evaluate novel cytosine-based inhibitors of TET enzymes.
• To identify small molecule probes for studying epigenetics.
• To develop potential therapeutic agents targeting DNA methylation.

Main Methods:

• Chemical synthesis of novel cytosine-based compounds.
• Enzyme inhibition assays against TET1, TET2, and DNMT3a.
• In silico modeling of TET enzyme active sites.

Main Results:

• Identification of Bobcat339, a lead compound with mid-micromolar inhibitory activity against TET1 and TET2.
• Bobcat339 demonstrated selectivity, not inhibiting DNMT3a.
• In silico modeling provided rationale for inhibitor activity.

Conclusions:

• Novel cytosine-based TET enzyme inhibitors were successfully developed.
• Bobcat339 serves as a valuable molecular tool for epigenetics research.
• These findings offer a starting point for developing therapeutics targeting DNA methylation and gene transcription.